As with the MedPod, all of our products are developed following our Sanitas Pro Omnibus philosophy, setting a new standards in treatment and performance.
Carvasin™: The DCP Medication received the first waiver of an IND approved by the FDA in 35 years in recognition of Carvasin’s ability to mitigate heart attack and stroke with 92% efficacy and assure 8-10 years of longevity in good health. The culmination of several scientific disciplines, Carvasin prevents and treats heart attack and stroke in a simple, once-a-day treatment regimen that promises to eliminate the number one cause of fatalities in the U.S.
The Daya Syphilis Test is a unique Syphilis Screening Test based on the Toluidine Red Unheated Serum Test (TRUST). While approved by the FDA as a screening test, the DST parameters of specificity and sensitivity emulate confirmatory tests. The DST is currently being sold to the Department of Defense (DoD) at substantial savings and is the only biomedical syphilis screening test approved for purposes of deployable medical systems (DEPMEDS) by the U.S. military.
The D-Mantoux Test is a Purified Protein Derivative Test (PPD) for the diagnosis of Tuberculosis. It is the only PPD Test that uses multi-drug resistant bacteria seed stock in its manufacture. The D-Mantoux can be sold at half the costs of current PPD tests and, upon final FDA approval, will be distributed globally to reach the over two billion people testing positive for TB.